Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 52

1.

Tuberculosis: what we don't know can, and does, hurt us.

Russell DG, Barry CE 3rd, Flynn JL.

Science. 2010 May 14;328(5980):852-6. doi: 10.1126/science.1184784. Review.

2.

Interaction of Mycobacterium tuberculosis with the host: consequences for vaccine development.

Dietrich J, Doherty TM.

APMIS. 2009 May;117(5-6):440-57. doi: 10.1111/j.1600-0463.2009.02458.x. Review.

PMID:
19400867
3.

Host-directed therapy targeting the Mycobacterium tuberculosis granuloma: a review.

Kiran D, Podell BK, Chambers M, Basaraba RJ.

Semin Immunopathol. 2016 Mar;38(2):167-83. doi: 10.1007/s00281-015-0537-x. Epub 2015 Oct 28. Review.

5.

Host-pathogen interactions in latent Mycobacterium tuberculosis infection: identification of new targets for tuberculosis intervention.

Lin MY, Ottenhoff TH.

Endocr Metab Immune Disord Drug Targets. 2008 Mar;8(1):15-29. Review.

PMID:
18393920
6.

Mycobacterium tuberculosis metabolism.

Warner DF.

Cold Spring Harb Perspect Med. 2014 Dec 11;5(4). pii: a021121. doi: 10.1101/cshperspect.a021121. Review.

7.

Heterogeneity in tuberculosis.

Cadena AM, Fortune SM, Flynn JL.

Nat Rev Immunol. 2017 Nov;17(11):691-702. doi: 10.1038/nri.2017.69. Epub 2017 Jul 24. Review.

PMID:
28736436
8.

The impact of transcriptomics on the fight against tuberculosis: focus on biomarkers, BCG vaccination, and immunotherapy.

Zárate-Bladés CR, Silva CL, Passos GA.

Clin Dev Immunol. 2011;2011:192630. doi: 10.1155/2011/192630. Epub 2010 Dec 20. Review.

9.

The challenge of new drug discovery for tuberculosis.

Koul A, Arnoult E, Lounis N, Guillemont J, Andries K.

Nature. 2011 Jan 27;469(7331):483-90. doi: 10.1038/nature09657. Review.

PMID:
21270886
10.

Cytokine and lipid mediator networks in tuberculosis.

Mayer-Barber KD, Sher A.

Immunol Rev. 2015 Mar;264(1):264-75. doi: 10.1111/imr.12249. Review.

11.

Development of new vaccines and drugs for TB: limitations and potential strategic errors.

Orme IM.

Future Microbiol. 2011 Feb;6(2):161-77. doi: 10.2217/fmb.10.168. Review.

12.

TB drug development: immunology at the table.

Nathan C, Barry CE 3rd.

Immunol Rev. 2015 Mar;264(1):308-18. doi: 10.1111/imr.12275. Review.

13.

A case for a neonatal, low-dose BCG vaccination trial.

Bretscher P, Menon J, Power C, Uzonna J, Wei G.

Scand J Infect Dis. 2001;33(4):253-7. Review.

PMID:
11345215
14.

Immunological requirements for a subunit vaccine against tuberculosis.

Elhay MJ, Andersen P.

Immunol Cell Biol. 1997 Dec;75(6):595-603. Review.

PMID:
9492199
15.

Tuberculosis vaccine development: recent progress.

Orme IM, McMurray DN, Belisle JT.

Trends Microbiol. 2001 Mar;9(3):115-8. Review.

PMID:
11239788
16.

Immunological biomarkers of tuberculosis.

Walzl G, Ronacher K, Hanekom W, Scriba TJ, Zumla A.

Nat Rev Immunol. 2011 May;11(5):343-54. doi: 10.1038/nri2960. Epub 2011 Apr 8. Review.

PMID:
21475309
17.

[Novel vaccines against M. tuberculosis].

Okada M.

Kekkaku. 2006 Dec;81(12):745-51. Review. Japanese.

PMID:
17240920
18.

Tuberculosis vaccines: hopes and hurdles.

Ahsan MJ, Garg SK, Vashistha B, Sharma P.

Infect Disord Drug Targets. 2013 Oct;13(5):318-21. Review.

PMID:
24304353
19.

Host-pathogen systems for early drug discovery against tuberculosis.

Trofimov V, Costa-Gouveia J, Hoffmann E, Brodin P.

Curr Opin Microbiol. 2017 Oct;39:143-151. doi: 10.1016/j.mib.2017.11.017. Epub 2017 Nov 24. Review.

PMID:
29179041
20.

A novel TB vaccine; towards a strategy based on our understanding of BCG failure.

Agger EM, Andersen P.

Vaccine. 2002 Nov 22;21(1-2):7-14. Review.

PMID:
12443657

Supplemental Content

Support Center